Gland Pharma has received a tentative approval from the United States Food and Drug Administration (USFDA) for Cangrelor for Injection, 50 mg/vial Single-Dose Vials. The company is amongst one of the first to files for this product and may be eligible for 180 days of generic drug exclusivity. The company will launch the product with its marketing partner on receipt of final approval.
Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in over 60 countries, including the US, Canada, Australia and India.
